Gefitinib-d6

Gefitinib-d₆ is intended for use as an internal standard for the quantification of gefitinib by GC- or LC-MS. Gefitinib is an EGFR inhibitor (IC₅₀s = 0.023-0.079 μM). It inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC₅₀s = 0.2-0.4 μM). Gefitinib (0.1 to 1 μM) induces apoptosis and inhibits EGFR autophosphorylation in the same cells. In vivo, gefitinib (1.25, 2.5, and 5 mg/kg) reduces tumor volume and increases survival in a GEO mouse xenograft model. Formulations containing gefitinib have been used in the treatment of non-small cell lung cancer (NSCLC).

Gefitinib-d6 is the labeled version of Gefitinib (G304000), which is an antineoplastic.

[1] JOHN MENDELSOHN  Jose B. The EGF receptor family as targets for cancer therapy[J]. Oncogene, 2000, 19 56: 6550-6565. DOI: 10.1038/sj.onc.1204082
[2] F CIARDIELLO. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.[J]. Clinical Cancer Research, 2000, 6 5: 2053-2063.